Erratum: Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer (Journal of Clinical Oncology (2013) 31 (2586-2592) DOI: 10.1200/JCO.2012.46.2408);Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer

Journal of Clinical Oncology

Volumn 31, Issue 20, 2013, Pages 2586-2592

  Baselga, José ^a   Gómez, Patricia ^b   Greil, Richard ^e   Braga, Sofia ^c   Climent, Miguel A ^c   Wardley, Andrew M ^g   Kaufman, Bella ^h   Stemmer, Salomon M ⁱ   Pego, António ^f   Chan, Arlene ^j   Goeminne, Jean Charles ^k   Graas, Marie Pascale ^l   Kennedy, M John ⁿ   Ciruelos Gil, Eva Maria ^d   Schneeweiss, Andreas ^o   Zubel, Angela ^p   Groos, Jutta ^p   Melezínkova, Helena ^p   Awada, Ahmad ^m  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Catala Oncology Institute   (Spain)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

^f Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ Davidoff Center   (Israel)

^j Mount Hospital   (Australia)

^k Clinique & Maternite Sainte Elisabeth Namer   (Belgium)

^l Clinique Saint Joseph   (Belgium)

^m JULES BORDET INSTITUTE   (Belgium)

ⁿ ST JAMES S HOSPITAL   (Ireland)

^o UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^p MERCK KGAA   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR;

ACNE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; TRIPLE NEGATIVE BREAST CANCER; ADULT; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84883858492     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.76.9976     Document Type: Erratum

References (30)

1. Cheang MC, Voduc D, Bajdik C, et al: Basallike breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368-1376, 2008
2. Kwan ML, Kushi LH, Weltzien E, et al: Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11:R31, 2009
3. Dent R, Trudeau M, Pritchard KI, et al: Triplenegative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434, 2007
4. Isakoff SJ: Triple-negative breast cancer: Role of specific chemotherapy agents. Cancer J 16:53-61, 2010
5. Kassam F, Enright K, Dent R, et al: Survival outcomes for patients with metastatic triplenegative breast cancer: Implications for clinical practice and trial design. Clin Breast Cancer 9:29-33, 2009
6. Corkery B, Crown J, Clynes M, et al: Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 20:862-867, 2009
7. Baselga J, Norton L, Masui H, et al: Antitumor effects of doxorubicin in combination with antiepidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327-1333, 1993
8. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819, 2004
9. Silver DP, Richardson AL, Eklund AC, et al: Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145-1153, 2010
10. Staudacher L, Cottu PH, Dieras V, et al: Platinum-based chemotherapy in metastatic triplenegative breast cancer: The Institut Curie experience. Ann Oncol 22:848-856, 2011
11. Uhm JE, Park YH, Yi SY, et al: Treatment outcomes and clinicopathologic characteristics of triplenegative breast cancer patients who received platinumcontaining chemotherapy. Int J Cancer 124:1457-1462, 2009
12. Balin-Gauthier D, Delord JP, Pillaire MJ, et al: Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 98:120-128, 2008
13. Dittmann K, Mayer C, Rodemann HP: Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76:157-161, 2005
14. Aboud-Pirak E, Hurwitz E, Pirak ME, et al: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80:1605-1611, 1988
15. Fan Z, Baselga J, Masui H, et al: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53:4637-4642, 1993
16. Hoadley KA, Weigman VJ, Fan C, et al: EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8:258, 2007
17. Baselga J, Trigo JM, Bourhis J, et al: Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23:5568-5577, 2005
18. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
19. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671, 2009
20. Carey LA: Directed therapy of subtypes of triple-negative breast cancer. Oncologist 15:49-56, 2010 (suppl 5)
21. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
22. Regan MM, Viale G, Mastropasqua MG, et al: Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98:1571-1581, 2006
23. Carlson RW, Moench SJ, Hammond ME, et al: HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 4:S1-S22, 2006; quiz S23-S24 (suppl 3)
24. Lynch TJ, Patel T, Dreisbach L, et al: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911-917, 2010
25. Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373:1525-1531, 2009
26. Carey LA, Rugo HS, Marcom PK, et al: TBCRC 001: Randomized phase III study of cetuximab in combination with carboplatin in Stage IV triple-negative breast cancer. J Clin Oncol 30:2615-2623, 2012
27. O'Shaughnessy J, Weckstein D, Vukelja S: Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 106:S32-S33, 2007 (suppl 1; abstr 308)
28. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007
29. Van Cutsem E, Kohne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
30. Khambata-Ford S, O'Shaughnessy J, Brickman D, et al: Candidate predictive biomarkers of cetuximab benefit in triple-negative breast cancer. J Clin Oncol 28:127s, 2010 (abstr 1056)